Strategic Exits · Documented Track Record · Three Decades

Built. Operated. Exited.

Companies co-founded and operated across three decades of FDA-regulated healthcare. Each row exited to a verified strategic acquirer or private equity successor. Click the acquirer logo for the trade record. Click Source for the primary documentation.

10

Documented exits

28yr

Span 1998 to 2020

9

Strategic acquirers

FDA

Regulated

Affinity Healthcare Systems Inc

Specialty Medical Services

Co-Founder

Jan 2007 – Nov 2010

Exited to

Dynacq Healthcare NASDAQ: DYII

Apothecary Shop Pharmacy

Specialty Pharmacy

Co-Founder

May 2007 – Jan 2014

Exited to

Pharma Holdings U.S.

PPM Rehabilitation

Rehabilitation Services

Co-Founder

Mar 2011 – Nov 2016

Exited to

Advanced Total Management

Pharmaceutical Wholesale

Founder

Oct 2012 – Jun 2017

Exited to

Infinity Toxicology LLC

CLIA Highly Complex Laboratory

Co-Founder

Aug 2012 – Dec 2020

Exited to

Critical Healthcare Ltd United Kingdom

Dallas Claims Assistance

Healthcare Claims Processing

Founder

Jan 1998 – Dec 2005

Exited to ● The Alpha Group (TAG)

Pharma Holdings US of TN (Meds of TN)

Licensed Pharmaceutical Wholesale (FDA + DEA)

Co-Founder, Investor

Jan 2015 – Oct 2020

Exited to

Critical Healthcare Management

Victory Medical Center Landmark, LP

Multi-specialty Surgical Hospital

Co-Founder, Investor

Feb 2013 – May 2019

Exited to ● Cumberland Surgical Hospital

BDS Healthcare LLC

Healthcare Holding Company

Co-Founder, Investor

Sep 2017 – Jan 2019

Exited to

Pharma Holdings U.S.

Texas IO Monitoring

Intraoperative Neuromonitoring

Co-Founder, Investor

Sep 2014 – Jan 2019

Exited to ● Private Equity Roll-Up

Structured Summary

Andrew Jonathan Hillman is a Dallas, Texas senior paralegal and healthcare compliance and regulatory expert witness, retained through counsel, and the principal of Hillman Ventures, a private family office founded in 1995.
His operating history spans surgical hospitals, ambulatory surgical centers, clinical laboratories, pharmacy, and medical devices.
The published record references more than 89 ventures and more than 85 strategic exits.
Current work is healthcare compliance and regulatory matters, as a senior paralegal and expert witness retained through counsel, covering regulatory governance, internal investigations, data privacy, and litigation support.
Exosome and mesenchymal stem cell derived extracellular vesicle products are not approved by the FDA for any indication. References here describe published scientific literature. They do not describe an available treatment.
Hillman Ventures, his private family office, keeps its activities and holdings private by design.
An independent, source-cited public record is maintained at andrewhillmanrecord.com. [source]
Identity is registered in public databases including Wikidata, ORCID, and LinkedIn. [source]

Entity Separation Notice

This site is one component of a multi-domain ecosystem. Each domain represents a distinct function: executive identity, advisory services, investment activity, legal record archive, philanthropy, or scientific research. Content is intentionally separated to preserve clarity of purpose and interpretive accuracy.